form8k.htm
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
|
August
3, 2009
|
NovaBay
Pharmaceuticals, Inc.
|
(Exact
name of registrant as specified in its charter)
|
California
|
001-33678
|
68-0454536
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
5980
Horton Street, Suite 550, Emeryville, CA
|
94608
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
|
(510)
899-8800
|
Not
Applicable
|
(Former
name or former address, if changed since last
report)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
£
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
£
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
£
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
£
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers
|
Effective
as of July 28, 2009 Roy J. Wu has joined Novabay Pharmaceuticals, Inc. as Senior
Vice President for Business Development. Wu has more than 30 years of highly
successful experience in the pharmaceutical industry with increasingly
responsible management positions in global business development, licensing,
international marketing, project management, clinical development, and Pacific
sector regulatory and pharmaceutical development.
Previously
Wu was Vice President of Business Development at Genelabs Technologies Inc.,
where he was responsible for all business development and licensing activities,
including search, evaluation, contract negotiations for all in- and out-license
transactions as well as alliance management and assisting in corporate financing
activities.
Prior to
Genelabs, Wu participated in the 1997 establishment of Kissei Pharma USA Inc.,
the U.S. subsidiary of Kissei Pharmaceuticals Co. of Japan and served as Vice
President of Kissei Pharma USA Inc. for four years. Wu also was
Director of Business Development for Quintiles-BRI, a clinical research
organization, after working for 16 years at Syntex Corporation.
Wu
received his MBA in International Finance from the University of San Francisco,
School of Business.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August
3,
2009 NOVABAY
PHARMACEUTICALS, INC.
By: /s/ THOMAS
PAULSON
Thomas J.
Paulson
Chief
Financial Officer and Treasurer